The global Virus Cryopreservation market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.
Virus cryopreservation is a biotechnology that allows long-term preservation of virus in living tissues or in suspension medium by freezing them at very low temperatures, usually below -70°C. The aim of virus cryopreservation is to maintain the viability and infectivity of the virus without altering its genetic stability. Virus cryopreservation requires the use of cryo-protectant agents, such as glycerol, dimethyl sulfoxide (DMSO) or fetal bovine serum (FBS), to prevent ice crystal formation and damage to the virus structure.
Global key Virus Cryopreservation players cover:
- ATCC
- Kerafast
- Virovek
- Virusys Corporation
- Microbix Biosystems
- Eureka Therapeutic
- Vigene Biosciences
- Oxford Biomedica
- Cobra Biologics
- Lonza
- BioReliance
Segmentation by Type:
- Plant Virus Freezing Solution
- Animal Virus Freezing Solution
Segmentation by Application:
- Medical
- Scientific Research
Market by Region:
- Americas
- APAC
- Europe
- Middle East & Africa
Key Questions Addressed in this Report:
- What is the 10-year outlook for the global Virus Cryopreservation market?
- What factors are driving Virus Cryopreservation market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Virus Cryopreservation market opportunities vary by end market size?
- How does Virus Cryopreservation break out by Type, by Application?
Frequently Asked Questions
What is the USP of the report? expand_more
What are the key content of the report? expand_more
- Global Market Players
- Geopolitical regions
- Consumer Insights
- Technological advancement
- Historic and Future Analysis of the Market